Nanopharmaceuticals are a revolutionary new approach to designing drugs within ultra-small particles and enhancing their properties with the goal of creating improved therapies for fighting disease. Cerulean is deploying its nanoparticles platform, along with its specialized capabilities and experienced management team to generate a pipeline of highly differentiated nanopharmaceutical products.

Cerulean is discovering and developing nanopharmaceuticals for diseases with high unmet medical need. By integrating a suite of proprietary technologies, the company is developing nanopharmaceuticals designed to profoundly improve clinical outcome by preferentially directing drug-containing nanoparticles to diseased tissues, releasing the drug in target cells over a sustained period of time, and minimizing chronic systemic exposure.

This fundamentally different approach can be applied to a wide range of drug molecules, transforming both new chemical entities and clinically validated drugs into significant commercial franchises.

Cerulean’s technology platforms will greatly enhance research and development productivity, enable innovative product life cycle management, and create more versatile combination therapy product opportunities. Leading indications for nanopharmaceuticals include cancer, inflammation, and cardiovascular diseases.